North America Histopathology Services Market
Histopathology services are used in the examination of biological tissues for the diagnosis of diseases. The procedure includes microscopic examination of tissues. With the help of imaging techniques biopsy tissues can now be obtained from certain inaccessible sites such as pancreas and the peritoneum.
Strategic insights for the North America Histopathology Services provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.
| Report Attribute | Details |
|---|---|
| Market size in 2021 | US$ 9,283.83 Million |
| Market Size by 2028 | US$ 13,902.74 Million |
| Global CAGR (2021 - 2028) | 5.9% |
| Historical Data | 2019-2020 |
| Forecast period | 2022-2028 |
| Segments Covered |
By Type of Examination
|
| Regions and Countries Covered | North America
|
| Market leaders and key company profiles |
The geographic scope of the North America Histopathology Services refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.
The North America histopathology services market is expected to reach US$ 13,902.74 million by 2028 from US$ 9,283.83 million in 2021; it is estimated to grow at a CAGR of 5.9% from 2021 to 2028. Factors such as rising demand for biologics and increasing prevalence of chronic diseases drive the market growth. However, limitations associated with histopathology and immunohistochemistry hinder the North America histopathology services market growth.
The histopathology market for biologics is growing at an unprecedented rate owing to expansion of biologics pipeline, increase in manufacturing complexity, and shift in the focus of companies toward core activities. A significant boom has been witnessed in the manufacturing of biologics. There is pressing need of scaling up the production once novel technologies get approval from the domestics and international approving bodies. The competition within the biopharmaceutical sector is becoming fierce with more biological products and biosimilars being introduced in the market. Biologics manufacturers strive to keep manufacturing costs low, deliver high-quality drugs, improve process efficiency, and accelerate market entry. Inputs from expert histopathologists have been playing a significant role in the understanding of tumor biology as well as in the pathogenic mechanism of various microorganisms. These findings and inferences are utilized by dedicated organizations offering histopathological services. According to the Food and Drug Administration, as of September 2019, there were more than 350 biologics commercially available in the US biopharmaceutical market. Clinical trials and drug discovery procedures of these drugs are based on intrinsic histopathological studies conducted using high-tech equipment, under expert supervision. Thus, the increasing number of biologic treatment in the pipeline that require histopathological interventions is propelling the growth of the North America histopathology services market. Further, the escalating incidence of chronic diseases, such as cardiovascular disorders, neurological disorders, autoimmune disorders, and cancer, is a leading causes of mortalities and disabilities worldwide. Researchers and therapists are exploring therapies for treating these diseases; they conduct detailed histopathological analysis to understand the pathophysiology of these diseases for designing therapies, which is contributing to the histopathology services market growth in North America.
The COVID-19 pandemic has impacted every aspect of the diagnostics industry in North America, including histopathology. In the last few months, the number of patient visits to hospitals has reduced significantly, despite emergency and OPD services being available in hospitals. Due to lockdowns enforced in many countries, the number of elective and cancer surgeries have reduced significantly. Moreover, due to the robust increase in the incidence of COVID- 19, pathology laboratories are now prioritizing and focusing on COVID-19 diagnosis. A rapid increase in the number of infected patients in the US and Canada is hampering the growth of the histopathology services market performance in the region.
The North America histopathology services market, by type of examination, is segmented into surgical specimen, breast biopsy, lung biopsy, renal biopsy, gastrointestinal biopsy, pancreatic biopsy, skin tissue biopsy, testicular biopsy, and others. In 2021, the surgical specimen segment is likely to hold the largest share of the market, and it is further expected to register the highest CAGR during 2021–2028.
Based on end user, the North America histopathology services market is segmented into diagnostic laboratories and reference laboratories, research institutes, and others. The diagnostic laboratories and reference laboratories segment is likely to hold the largest share of the market in 2021, and it is anticipated to register the highest CAGR during the forecast period.
A few of the primary and secondary sources associated with this report on the North America histopathology services market are the Centers for Disease Control and Prevention (CDC), Center for Drug Evaluation and Research (CDER), and Food and Drug Administration (FDA).
The North America Histopathology Services Market is valued at US$ 9,283.83 Million in 2021, it is projected to reach US$ 13,902.74 Million by 2028.
As per our report North America Histopathology Services Market, the market size is valued at US$ 9,283.83 Million in 2021, projecting it to reach US$ 13,902.74 Million by 2028. This translates to a CAGR of approximately 5.9% during the forecast period.
The North America Histopathology Services Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the North America Histopathology Services Market report:
The North America Histopathology Services Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The North America Histopathology Services Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the North America Histopathology Services Market value chain can benefit from the information contained in a comprehensive market report.
Office No. 1011, First floor, Farena Corporate Park, Magarpatta-Mundhwa road, Pune - 411028, Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For North America Histopathology Services Market
